In recent years, psychedelic therapy has gone from fringe curiosity to front-page science. The idea that substances like psilocybin — the psychoactive compound found in so-called “magic mushrooms” — could lift the fog of depression has sparked both fascination and controversy.
At a manufacturing hub in Meadowbrook, south of Brisbane, four high-security vaults are lined with boxes and bottles of cannabis, MDMA and psilocybin capsules.
Bioxyne CEO and Managing Director Sam Watson talked with Proactive about the company’s major developments across medical psychedelics and cannabis in 2025, highlighting growing domestic and international momentum.
Brisbane manufacturer Bioxyne delivered record quarterly revenue of A$17.2 million in Q2 FY26, a 21% increase on Q1 and a 112% life on the previous corresponding year.
Medicinal cannabis manufacturer Bioxyne has received its first order of GMP-manufactured psilocybin capsules for investigational use in treatment-resistant depression.
BLS Pharmaceuticals Ltd (BLS:ASX) is an international healthcare, life sciences and novel medicines development company with operations in Australia (head office), United Kingdom, Japan, Czechia, Germany, and the United States serving customers world-wide.
BLS Pharmaceuticals Limited (ASX: BLS) is committed to maintaining the highest standards of corporate governance, transparency, and ethical conduct across all aspects of its operations. The following governance documents outline the Company’s core policies and principles that guide its leadership, decision-making processes, and stakeholder responsibilities.
BLS Pharmaceuticals Limited (ASX: BLS) is an international Australian life sciences company headquartered in Sydney, and parent company of the Breathe Life Sciences Group. BLS Pharmaceuticals Limited and wholly owned subsidiary Breathe Life Sciences manufacture and distribute novel medicines (cannabis, MDMA, Psilocybin) and consumer health products (CBD, functional mushrooms, other) in Australia, Europe, UK, Japan, and USA. In Australia, Breathe Life Sciences holds a TGA manufacturing license, c
BLS Pharmaceuticals Ltd is a healthcare business and the parent company of the Breathe Life Sciences Group, focused on life sciences, novel therapeutic goods, pharmaceutical manufacturing and wholesaling.
BLS Pharmaceuticals reports its highest-ever revenue and earnings for fiscal year 2026, driven by expanded international operations. The company’s growth stems from increased global demand for its pharmaceutical products. Financial details and specific markets contributing to the expansion are not disclosed in the article.
BLS reports record revenue and earnings for its 2026 financial year, driven by increased manufacturing output and a rising number of international clients. The company strengthens its position as a global supplier of regulated medicines through accelerated overseas growth. Higher demand from international markets contributes to its financial performance.
Bioxyne’s subsidiary **BLS** secures an upgraded wholesale licence covering **MDMA and psilocybin finished products**, expanding its ability to distribute regulated psychedelic therapies in Australia. The licence amendment allows for broader handling of controlled substances used in mental health treatments. Authorities approve the move as demand grows for psychedelic-assisted therapies in clinical and research settings.
Bioxyne Limited’s subsidiary, **Breathe Life Sciences (BLS)**, obtains Australia’s first **Good Manufacturing Practice (GMP) licence** for producing **psilocybin and MDMA**. The licence covers controlled manufacturing of these substances for medical or therapeutic use. This milestone positions BLS as a key player in Australia’s emerging psychedelic-assisted therapy sector.
Bioxyne’s subsidiary **Breathe Life Sciences (BLS)** obtains Australia’s first **Good Manufacturing Practice (GMP) license** for producing **medical cannabis**, expanding its regulatory approvals in psychedelic and cannabis-based therapies. The license covers manufacturing processes critical for clinical and commercial supply of controlled substances. Bioxyne (ASX:BXN) highlights this milestone as a key step toward scaling therapeutic production in Australia.